Works matching DE "GEFITINIB"
Results: 814
Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier-Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor.
- Published in:
- Advanced Functional Materials, 2014, v. 24, n. 35, p. 5482, doi. 10.1002/adfm.201400456
- By:
- Publication type:
- Article
Erlotinib and gefitinib responsiveness in head and neck cancer cell lines-a comparing analysis with cetuximab.
- Published in:
- Clinical Oral Investigations, 2016, v. 20, n. 4, p. 759, doi. 10.1007/s00784-015-1566-5
- By:
- Publication type:
- Article
Validation of HPLC Method for Quantitative Determination of Gefitinib in Polymeric Nanoformulation.
- Published in:
- Pharmaceutical Chemistry Journal, 2017, v. 51, n. 2, p. 159, doi. 10.1007/s11094-017-1575-6
- By:
- Publication type:
- Article
A Convenient and Easy Purification Approach to High-Yield Synthesis of Gefitinib as an Anticancer Agent from Isovaniline.
- Published in:
- Pharmaceutical Chemistry Journal, 2014, v. 48, n. 8, p. 520, doi. 10.1007/s11094-014-1141-4
- By:
- Publication type:
- Article
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.
- Published in:
- JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/51381
- By:
- Publication type:
- Article
Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.
- Published in:
- Communications Biology, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42003-024-07339-3
- By:
- Publication type:
- Article
Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2017, v. 32, n. 1, p. 1229, doi. 10.1080/14756366.2017.1368504
- By:
- Publication type:
- Article
Updates from ASCO 2014 and ESMO 2014.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 1, p. 23
- Publication type:
- Article
A study on treatment of locally advanced squamous cell carcinoma of head and neck with radiation along with cisplatin or gefitinib.
- Published in:
- Medica Innovatica, 2022, v. 11, n. 2, p. 1
- By:
- Publication type:
- Article
Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.
- Published in:
- Dermatology & Therapy, 2017, v. 7, n. 1, p. 133, doi. 10.1007/s13555-016-0163-0
- By:
- Publication type:
- Article
Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00260
- By:
- Publication type:
- Article
Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects.
- Published in:
- Frontiers in Pharmacology, 2018, p. N.PAG, doi. 10.3389/fphar.2018.00849
- By:
- Publication type:
- Article
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644
- By:
- Publication type:
- Article
Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip.
- Published in:
- Biosensors (2079-6374), 2022, v. 12, n. 8, p. 618, doi. 10.3390/bios12080618
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway.
- Published in:
- Journal of Cancer, 2024, v. 15, n. 13, p. 4259, doi. 10.7150/jca.94438
- By:
- Publication type:
- Article
Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
- Published in:
- Cellular Oncology (2211-3428), 2022, v. 45, n. 5, p. 913, doi. 10.1007/s13402-022-00696-3
- By:
- Publication type:
- Article
Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
- Published in:
- Cellular Oncology (2211-3428), 2021, v. 44, n. 6, p. 1231, doi. 10.1007/s13402-021-00632-x
- By:
- Publication type:
- Article
Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial–mesenchymal transition through targeting major vault protein (MVP).
- Published in:
- Cellular Oncology (2211-3428), 2021, v. 44, n. 1, p. 109, doi. 10.1007/s13402-020-00556-y
- By:
- Publication type:
- Article
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
- Published in:
- Cellular Oncology (2211-3428), 2014, v. 37, n. 5, p. 377, doi. 10.1007/s13402-014-0198-0
- By:
- Publication type:
- Article
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
- Published in:
- Cellular Oncology (2211-3428), 2013, v. 36, n. 4, p. 277, doi. 10.1007/s13402-013-0133-9
- By:
- Publication type:
- Article
Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
- Published in:
- Application of Clinical Genetics, 2017, v. 10, p. 49, doi. 10.2147/TACG.S103471
- By:
- Publication type:
- Article
Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation.
- Published in:
- Clinical Epidemiology, 2022, v. 14, p. 1135, doi. 10.2147/CLEP.S373291
- By:
- Publication type:
- Article
Lung Cancer Drug and Companion Diagnostic Test Are Approved.
- Published in:
- JAMA: Journal of the American Medical Association, 2015, v. 314, n. 7, p. 662, doi. 10.1001/jama.2015.9768
- By:
- Publication type:
- Article
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.
- Published in:
- BMC Research Notes, 2015, v. 8, p. 1, doi. 10.1186/s13104-015-1762-z
- By:
- Publication type:
- Article
Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.
- Published in:
- Clinical Respiratory Journal, 2017, v. 11, n. 3, p. 346, doi. 10.1111/crj.12343
- By:
- Publication type:
- Article
Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry.
- Published in:
- Rapid Communications in Mass Spectrometry: RCM, 2021, v. 35, n. 1, p. 1, doi. 10.1002/rcm.8955
- By:
- Publication type:
- Article
Increasing progression-free survival in non-small cell lung cancer.
- Published in:
- British Journal of Hospital Medicine (17508460), 2009, v. 70, n. 9, p. 498
- Publication type:
- Article
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy.
- Published in:
- Journal of Nanobiotechnology, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12951-020-00759-3
- By:
- Publication type:
- Article
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
- Published in:
- BMC Complementary & Alternative Medicine, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1472-6882-14-165
- By:
- Publication type:
- Article
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
- Published in:
- BMC Bioinformatics, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s12859-015-0522-3
- By:
- Publication type:
- Article
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
- Published in:
- BMC Bioinformatics, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s12859-015-0522-3
- By:
- Publication type:
- Article
Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer.
- Published in:
- Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01780-4
- By:
- Publication type:
- Article
Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2018, v. 14, n. 1, p. 23, doi. 10.1111/ajco.12687
- By:
- Publication type:
- Article
Sustained response to standard dose osimertinib in a patient with plasma T790M-positive leptomeningeal metastases from primary lung adenocarcinoma.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2017, v. 13, n. 6, p. 428, doi. 10.1111/ajco.12673
- By:
- Publication type:
- Article
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2017, v. 13, n. 5, p. e189, doi. 10.1111/ajco.12273
- By:
- Publication type:
- Article
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2012, v. 8, n. 3, p. 232, doi. 10.1111/j.1743-7563.2012.01518.x
- By:
- Publication type:
- Article
In this Issue.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2012, v. 8, n. 3, p. i, doi. 10.1111/j.1743-7563.2012.01454.x
- Publication type:
- Article
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2012, v. 8, n. 3, p. 267, doi. 10.1111/j.1743-7563.2011.01509.x
- By:
- Publication type:
- Article
FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells.
- Published in:
- Acta Pharmacologica Sinica, 2012, v. 33, n. 5, p. 675, doi. 10.1038/aps.2011.188
- By:
- Publication type:
- Article
The economic evaluation of personalised oncology medicines: ethical challenges.
- Published in:
- Medical Journal of Australia, 2013, v. 199, n. 7, p. 471, doi. 10.5694/mja13.10046
- By:
- Publication type:
- Article
Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 71, n. 2, p. 1261, doi. 10.1007/s12013-014-0286-9
- By:
- Publication type:
- Article
Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes.
- Published in:
- Cell Biochemistry & Biophysics, 2014, v. 70, n. 1, p. 553, doi. 10.1007/s12013-014-9955-y
- By:
- Publication type:
- Article
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
- Published in:
- Langenbeck's Archives of Surgery, 2014, v. 399, n. 7, p. 879, doi. 10.1007/s00423-014-1235-1
- By:
- Publication type:
- Article
Arsenic Attenuates Heparin-Binding EGF-Like Growth Factor/EGFR Signaling That Promotes Matrix Metalloprotease 9-Dependent Astrocyte Damage in the Developing Rat Brain.
- Published in:
- Toxicological Sciences, 2018, v. 162, n. 2, p. 406, doi. 10.1093/toxsci/kfx264
- By:
- Publication type:
- Article
Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 2, p. e2255050, doi. 10.1001/jamanetworkopen.2022.55050
- By:
- Publication type:
- Article